Hannah A. Valantine's most recent trade in Caredx Inc was a trade of 28,679 Common Stock done at an average price of $36.1 . Disclosure was reported to the exchange on July 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Caredx Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 36.14 per share. | 16 Jul 2026 | 28,679 | 36,786 (0%) | 0% | 36.1 | 1,036,588 | Common Stock |
| Caredx Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.19 per share. | 16 Jul 2026 | 16,048 | 60,340 (0%) | 0% | 14.2 | 227,721 | Common Stock |
| Caredx Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2026 | 16,048 | 0 | - | - | Stock Option (Right to Buy) | |
| Caredx Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.56 per share. | 16 Jul 2026 | 7,606 | 44,292 (0%) | 0% | 20.6 | 156,379 | Common Stock |
| Caredx Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2026 | 7,606 | 0 | - | - | Stock Option (Right to Buy) | |
| Caredx Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.96 per share. | 16 Jul 2026 | 5,125 | 65,465 (0%) | 0% | 8.0 | 40,795 | Common Stock |
| Caredx Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2026 | 5,125 | 24,011 | - | - | Stock Option (Right to Buy) | |
| Caredx Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 36.55 per share. | 16 Jul 2026 | 100 | 36,686 (0%) | 0% | 36.6 | 3,655 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2026 | 5,277 | 5,277 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2026 | 3,990 | 11,455 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 68.00 per share. | 22 Jun 2026 | 2,808 | 11,455 (0%) | 0% | 68 | 190,944 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.73 per share. | 22 Jun 2026 | 2,808 | 14,263 (0%) | 0% | 41.7 | 117,178 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2026 | 2,808 | 5,617 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 68.57 per share. | 22 Jun 2026 | 2,196 | 9,259 (0%) | 0% | 68.6 | 150,580 | Common Stock |
| Caredx Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 23.11 per share. | 12 Jun 2026 | 12,103 | 36,686 (0%) | 0% | 23.1 | 279,728 | Common Stock |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2026 | 9,795 | 48,789 (0%) | 0% | 0 | Common Stock | |
| Pacific Biosciences of California Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 223,492 | 223,492 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 72.00 per share. | 10 Mar 2026 | 8,671 | 7,465 (0%) | 0% | 72 | 624,312 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 8,671 | 17,343 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.36 per share. | 10 Mar 2026 | 8,671 | 16,136 (0%) | 0% | 27.4 | 237,239 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2025 | 25,484 | 25,484 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 66.07 per share. | 12 Nov 2025 | 25,484 | 7,465 (0%) | 0% | 66.1 | 1,683,728 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.45 per share. | 12 Nov 2025 | 25,484 | 32,949 (0%) | 0% | 48.5 | 1,234,700 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 44.03 per share. | 26 Jun 2025 | 1,891 | 398 (0%) | 0% | 44.0 | 83,261 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 44.01 per share. | 26 Jun 2025 | 1,542 | 7,465 (0%) | 0% | 44.0 | 67,863 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 44.11 per share. | 26 Jun 2025 | 876 | 9,007 (0%) | 0% | 44.1 | 38,640 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 44.13 per share. | 26 Jun 2025 | 398 | 2,289 (0%) | 0% | 44.1 | 17,562 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 8,425 | 8,425 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 6,589 | 8,353 (0%) | 0% | 0 | Common Stock | |
| Caredx Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 19.16 per share. | 18 Jun 2025 | 10,570 | 38,994 (0%) | 0% | 19.2 | 202,566 | Common Stock |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 12,103 | 49,564 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 10 Jun 2025 | 4,292 | 1,764 (0%) | 0% | 40 | 171,680 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 4,292 | 34,334 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.75 per share. | 10 Jun 2025 | 4,292 | 6,056 (0%) | 0% | 16.8 | 71,891 | Common Stock |
| Pacific Biosciences of California Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.75 per share. | 06 Mar 2025 | 12,875 | 14,639 (0%) | 0% | 16.7 | 215,656 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 12,875 | 38,626 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Sale of securities on an exchange or to another person at price $ 32.58 per share. | 06 Mar 2025 | 12,875 | 1,764 (0%) | 0% | 32.6 | 419,500 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 26,014 | 26,014 | - | - | Stock Option (Right to Buy) | |
| Pacific Biosciences of California Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 32,179 | 32,179 | - | - | Stock Option (right to buy) | |
| Pacific Biosciences of California Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 22,821 | 22,821 (0%) | 0% | 0 | Common Stock | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 16,048 | 16,048 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 16,048 | 16,048 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 10,570 | 37,461 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Valantine A. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.45 per share. | 15 Feb 2024 | 2,915 | 4,679 (0%) | 0% | 8.5 | 24,632 | Common Stock |
| BridgeBio Pharma Inc | A. Hannah Valantine | Director | Sale of securities on an exchange or to another person at price $ 37.75 per share. | 15 Feb 2024 | 2,915 | 1,764 (0%) | 0% | 37.7 | 110,041 | Common Stock |
| BridgeBio Pharma Inc | A. Valantine Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 2,915 | 93,261 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Valantine A. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 2,915 | 96,176 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Valantine A. Hannah | Director | Sale of securities on an exchange or to another person at price $ 37.97 per share. | 16 Jan 2024 | 2,915 | 1,764 (0%) | 0% | 38.0 | 110,683 | Common Stock |
| BridgeBio Pharma Inc | Valantine Hannah A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.45 per share. | 16 Jan 2024 | 2,915 | 4,679 (0%) | 0% | 8.5 | 24,632 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Purchase of securities on an exchange or from another person at price $ 13.18 per share. | 31 Dec 2023 | 1,891 | 1,891 (0%) | 0% | 13.2 | 24,923 | Common Stock |
| BridgeBio Pharma Inc | A. Hannah Valantine | Director | Purchase of securities on an exchange or from another person at price $ 12.68 per share. | 31 Dec 2023 | 1,542 | 3,433 (0%) | 0% | 12.7 | 19,553 | Common Stock |
| BridgeBio Pharma Inc | A. Valantine Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 2,915 | 99,091 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Valantine A. Hannah | Director | Sale of securities on an exchange or to another person at price $ 36.12 per share. | 15 Dec 2023 | 2,915 | 1,764 (0%) | 0% | 36.1 | 105,290 | Common Stock |
| BridgeBio Pharma Inc | Valantine Hannah A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.45 per share. | 15 Dec 2023 | 2,915 | 4,679 (0%) | 0% | 8.5 | 24,632 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 51,501 | 51,501 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 29,136 | 29,136 | - | - | Common Stock | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 18,844 | 26,891 (0%) | 0% | 0 | Common Stock | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 676 | 8,047 (0%) | 0% | 0 | Common Stock | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2022 | 422 | 7,371 (0%) | 0% | 0 | Common Stock | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 325 | 6,949 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 104,921 | 104,921 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 7,606 | 7,606 | - | - | Common Stock | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 4,863 | 6,624 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Purchase of securities on an exchange or from another person at price $ 14.23 per share. | 29 Dec 2021 | 1,764 | 1,764 (0%) | 0% | 14.2 | 25,102 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Purchase of securities on an exchange or from another person at price $ 14.24 per share. | 29 Dec 2021 | 1,752 | 3,294 (0%) | 0% | 14.2 | 24,948 | Common Stock |
| BridgeBio Pharma Inc | Valantine A. Hannah | Director | Purchase of securities on an exchange or from another person at price $ 13.18 per share. | 28 Dec 2021 | 1,891 | 1,891 (0%) | 0% | 13.2 | 24,923 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Purchase of securities on an exchange or from another person at price $ 12.68 per share. | 28 Dec 2021 | 1,542 | 3,433 (0%) | 0% | 12.7 | 19,553 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Purchase of securities on an exchange or from another person at price $ 12.68 per share. | 28 Dec 2021 | 1,542 | 1,542 (0%) | 0% | 12.7 | 19,553 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Purchase of securities on an exchange or from another person at price $ 13.16 per share. | 28 Dec 2021 | 796 | 2,687 (0%) | 0% | 13.2 | 10,475 | Common Stock |
| BridgeBio Pharma Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2021 | 50,968 | 50,968 | - | - | Stock Option (right to buy) | |
| Caredx Inc | Hannah A. Valantine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 131 | 1,761 (0%) | 0% | 0 | Common Stock |